Aragen Biologics launched CHOMax, an integrated CHO cell‑line development and early manufacturing platform designed to move antibody programs from DNA to IND‑enabling supply. The company says CHOMax streamlines workflows—from vector design and single‑cell cloning to Master Cell Bank creation—enabling an RCB in ~16 weeks and parallel CMC activities to compress timelines for antibody IND readiness. Aragen positioned CHOMax to service biotech sponsors seeking rapid, phase‑appropriate CMC data packages that align with global regulatory expectations and to reduce time-to‑first‑in‑human dosing.